J. Rogers

发表

Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

L. Lue, T. Beach, R. Rydel, 1999 .

Clinical trial of indomethacin in Alzheimer's disease

A. Kaszniak, J. Rogers, P. Mcgeer, 1993, Neurology.

Inflammation and Alzheimer's disease pathogenesis

Douglas Walker, Joseph Rogers, Lih-Fen Lue, 1996, Neurobiology of Aging.

Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia

Kewei Chen, Xiaofen Liu, Adam S. Fleisher, 2015, Alzheimer's & Dementia.

Enhanced cytotoxicity of amyloid β-peptide by a complement dependent mechanism

B. Bradt, N. Cooper, P. May, 1994, Neuroscience Letters.

Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms

D. Mastroeni, B. Bradt, J. Rogers, 2017, Alzheimer's & Dementia.

Complement activation by f8-amyloid in Alzheimer disease

P. Mcgeer, B. Bradt, I. Lieberburg, 2022 .

735 Molecular, immunohistochemical, and ultrastructural characterization of complement proteins, including C5b-9, in ALZHEIMER'S disease

L. Lue, D. Walker, P. Mcgeer, 1996, Neurobiology of Aging.

Immune actions in the nervous system: A brief review with special emphasis on Aalzheimer's disease

J. Rogers, J. Luber-Narod, 1988 .

Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.

M. Mintun, A. Fleisher, M. Sabbagh, 2011, Archives of neurology.

Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients

L. Lue, D. Walker, L. Brachova, 1996, Neurobiology of Aging.

Involvement of Microglial Receptor for Advanced Glycation Endproducts (RAGE) in Alzheimer's Disease: Identification of a Cellular Activation Mechanism

L. Lue, T. Beach, D. Walker, 2001, Experimental Neurology.

Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum

L. Lue, J. Rogers, 1992 .

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

L. Lue, T. Beach, R. Rydel, 1999, The American journal of pathology.

Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease

L. Lue, J. Rogers, 2001, Neurochemistry International.

M. Mesulam, E. Mufson, J. Rogers, 1987, Annals of neurology.

Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer’s Disease

L. Lue, D. Walker, P. Mcgeer, 1997, Neurobiology of Aging.

Modeling microglial activation in Alzheimer’s disease with human postmortem microglial cultures

L. Lue, D. Walker, J. Rogers, 2001, Neurobiology of Aging.

Complement activation by beta-amyloid in Alzheimer disease.

P. Mcgeer, B. Bradt, N. Cooper, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Peripheral complement interactions with amyloid b peptide in Alzheimer ’ s disease : 2 . Relationship to A b immunotherapy

B. Bradt, J. Rogers, C. Glavis-Bloom, 2017 .

The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007

D. Connor, M. Sabbagh, L. Lue, 2007, Cell and Tissue Banking.

Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease

S. Styren, W. H. Civin, J. Rogers, 1988, Neurobiology of Aging.

Demonstrating immune-related antigens in Alzheimer's disease brain tissue

E. Mufson, J. Rogers, 1990, Neurobiology of Aging.

Inflammatory Mediators in Alzheimer’s Disease

S. O’Barr, J. Rogers, 1997 .

Epidermal growth factor receptor expression in demented elderly: localization to vascular endothelial cells of brain, pituitary and skin

S. DeKosky, E. Mufson, S. Styren, 1993, Brain Research.

Epidermal growth factor receptor expression in demented and aged human brain

E. Mufson, S. Styren, W. H. Civin, 1990, Brain Research.

Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease.

L. Lue, B. Bradt, N. Cooper, 1992, Research in immunology.

Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain

S. Styren, W. H. Civin, J. Rogers, 1990, Experimental Neurology.

Anti-inflammatory drugs and Alzheimer disease

P. Mcgeer, E. Mcgeer, J. Rogers, 1990, The Lancet.

Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration.

L. Lue, J. Rogers, W. H. Civin, 1996, Journal of neuropathology and experimental neurology.

Correlation of the Expression Level of C1q mRNA and the Number of C1q-Positive Plaques in the Alzheimer Disease Temporal Cortex

T. Beach, D. Walker, I. Tooyama, 2001, Dementia and Geriatric Cognitive Disorders.

Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease.

L. Lue, L. Brachova, J. Rogers, 1993, Brain research. Molecular brain research.

Immune system associated antigens expressed by cells of the human central nervous system

Joseph Rogers, J. Rogers, Judith Luber-Narod, 1988, Neuroscience Letters.

Principles for central nervous system inflammation research: A call for a consortium approach

J. Rogers, 2018, Alzheimer's & Dementia.

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1

H. Javitz, A. Bergen, D. Mastroeni, 2018, Alzheimer's & Dementia.

Complement activation by neurofibrillary tangles in Alzheimer's disease

Virginia M. Y. Lee, L. Lue, B. Bradt, 2001, Neuroscience Letters.

Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation

J. Rogers, S. Webster, 1996 .

Multivalent Binding of Complement Protein C1q to the Amyloid β-Peptide (Aβ) Promotes the Nucleation Phase of Aβ Aggregation

C. Glabe, J. Rogers, S. Webster, 1995 .

Enhanced aggregation and β structure of amyloid β peptide after coincubation with C1Q

S. O’Barr, J. Rogers, S. Webster, 1994 .

Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.

J. Rogers, S. Webster, B. Bonnell, 1997, The American journal of pathology.

Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation.

C. Glabe, J. Rogers, S. Webster, 1995, Biochemical and biophysical research communications.

Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk

M. Sabbagh, J. Rogers, 2008, Neurology.

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy

B. Bradt, J. Rogers, C. Glavis-Bloom, 2018, Alzheimer's & Dementia.

Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms

D. Mastroeni, B. Bradt, J. Rogers, 2017, Alzheimer's & Dementia.